A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Sichuan Baili Pharmaceutical Co., Ltd.
538 participants
Jun 29, 2026
INTERVENTIONAL
Conditions
Summary
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 compared with the investigator's choice of protocol in patients with locally advanced or metastatic biliary tract cancer who have failed prior platinum-based chemotherapy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administration by intravenous infusion for a cycle of 3 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Oral administration for a cycle of 2 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07582315